Fluticasone furoate, umeclidinium and vilanterol inhalation
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Inhalation powder containing fluticasone furoate, umeclidinium bromide and vilanterol (as trifenatate).
Chronic obstructive pulmonary disease
Moderate to severe chronic obstructive pulmonary disease (COPD) in patients who are not adequately treated by a combination of an inhaled corticosteriod and a long acting beta2-agonist or a combination of a long acting beta2-agonist and long acting muscarinic antagonist.
One inhalation once daily, at the same time of the day.
Additional Dosage Information
If dose is missed, take the next dose at the usual time the following day.
Children under 18 years
Precautions and Warnings
Uncontrolled systemic infection
Benign prostatic hyperplasia
Glucose-galactose malabsorption syndrome
Moderate hepatic impairment
Narrow angle glaucoma
Recent history of pneumonia
Severe cardiovascular disorder
Unstable cardiac disorder
Advise visual disturbances may affect ability to drive or operate machinery
Ensure patient has a fast acting bronchodilator available
Check patient is using correct inhaler technique
If visual disturbances occur, perform ophthalmic evaluation
Monitor blood glucose closely in patients with diabetes mellitus
Monitor for signs/symptoms of pneumonia in patients at risk
May reduce serum potassium levels
Systemic effects possible with any inhaled corticosteroid
Do not withdraw this drug suddenly
Discontinue if paradoxical bronchospasm occurs
Discontinue if symptoms of acute angle closure glaucoma occur
Advise patient not to use for relief of acute attacks
Advise patient to rinse mouth with water after each dose
Advise patient to seek medical advice if treatment is ineffective
Consider issuing Steroid Treatment/Steroid Emergency Card
High dose:Advise patient to avoid chickenpox,measles etc; see Dr if exposed
Use regularly to maintain freedom from symptoms
Pregnancy and Lactation
Use the combination of fluticasone furoate, umeclidinium and vilanterol with caution during pregnancy.
The manufacturer recommends this medication is not used in pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animal studies show reproductive toxicity, however exposures were not clinically relevant. There is little data available on the use of fluticasone furoate, umeclidinium and vilanterol in pregnant women. A potential risk cannot be ruled out.
The combination of fluticasone furoate, umeclidinium and vilanterol is contraindicated during breastfeeding.
The manufacturer notes a decision should be made whether to cease breastfeeding or stop taking the medication. It is unknown whether fluticasone furoate, umeclidinium, vilanterol and their metabolites are excreted in human milk. Other corticosteroids, muscarinic antagonists and beta2-adrenergic agonists are detected in human milk, hence a risk to the infants cannot be excluded.
Candidiasis (mouth or throat)
Respiratory tract infection
Upper respiratory tract infection
Urinary tract infections
Last Full Review Date: February 2021
Summary of Product Characteristics: Trelegy Ellipta 92micrograms/55micrograms/22micrograms inhalation powder. GlaxoSmithKline UK. Revised September 2020.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 02 February 2021
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.